只有 BRCA 基因突变的患者才应该接受雄激素受体通路抑制剂和 PARP 抑制剂联合治疗转移性阉割耐药前列腺癌吗？答案是否定的。

{"title":"只有 BRCA 基因突变的患者才应该接受雄激素受体通路抑制剂和 PARP 抑制剂联合治疗转移性阉割耐药前列腺癌吗？答案是否定的。","authors":"Fred Saad","doi":"10.1016/j.euf.2024.07.015","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":"10 4","pages":"Pages 506-508"},"PeriodicalIF":4.8000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should Only Patients with BRCA Mutation Be Treated with a Combination of an Androgen Receptor Pathway Inhibitor and a PARP Inhibitor for Metastatic Castration-resistant Prostate Cancer? The Answer Is No\",\"authors\":\"Fred Saad\",\"doi\":\"10.1016/j.euf.2024.07.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\"10 4\",\"pages\":\"Pages 506-508\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405456924001536\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405456924001536","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}